Cardiac complications in children with acute COVID-19 vs multisystem inflammatory syndrome in children (MIS-C)

Hensley, M.; Goodman, Michael; Madani, Rohit; Jaggi, Preeti; Keesari, Rohali; Zhang, Qi; Oster, Matthew E.

doi:10.1016/j.ahj.2023.05.012

Cited by 2 publications

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They recorded interleukin (IL)-6 values and found that it was lower in patients who received combination therapy [19]. Similar findings were reported in other studies showing raised inflammatory markers [3,10,[20][21][22].…”

Section: Discussionsupporting

confidence: 79%

Multisystem Inflammatory Syndrome in Children (MIS-C) Post COVID-19 Infection: Diagnosis and Treatment from the Paediatric Intensive Care Unit (PICU) at a Tertiary Hospital in the Kingdom of Bahrain

Almosawi,

Mustafa,

Hassan

et al. 2023

Cureus

View full text Add to dashboard Cite

Background: Post coronavirus disease 2019 (COVID-19) infections, children presented with varying clinical manifestations of a Multisystem Inflammatory Syndrome in Children (MIS-C). The aim of our study is to identify the clinical manifestations upon admission to paediatric intensive care unit (PICU) and to identify how different treatments affected post-treatment outcomes.Methods: A retrospective cross-sectional study included 11 patients diagnosed with multisystem inflammatory syndrome based on the World Health Organization (WHO) classification and treated by intravenous immunoglobulin (IVIG) with/without corticosteroids.Results: There were six female and five male patients with an average age of 5.08±4.7 years. Ten had a confirmed positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serological antibody test or polymerase chain reaction (PCR) test, with one having only contact history. The most common systems affected by MIS-C were gastrointestinal and ophthalmological presentations. All presented with fever and raised inflammatory markers (erythrocyte sedimentation rate, C-reactive protein, procalcitonin, ferritin, ddimer, and lactate dehydrogenase). There was no statistical difference between both treatment groups. Clinical and inflammatory markers significantly improved in both groups.Conclusion: This study highlights an improved outcome associated with combination therapy, although there is no statistical significance between both groups.

show abstract

Section: Discussionsupporting

confidence: 79%

Multisystem Inflammatory Syndrome in Children (MIS-C) Post COVID-19 Infection: Diagnosis and Treatment from the Paediatric Intensive Care Unit (PICU) at a Tertiary Hospital in the Kingdom of Bahrain

Almosawi,

Mustafa,

Hassan

et al. 2023

Cureus

View full text Add to dashboard Cite

show abstract

“…The most common organ systems involved are gastrointestinal (87%), dermatologic/mucocutaneous (73%), cardiovascular (71%), respiratory (47%), and neurologic (22%) [25,30,32]. Cardiac involvement typically manifests as elevated troponins, brain natriuretic peptides, reduced ejection fraction, pericardial effusion, coronary artery dilation or aneurysm, and arrhythmias [31,33,34]. Laboratory abnormalities include elevated C-reactive protein (CRP), liver enzymes, Ddimer, lymphopenia, neutropenia, thrombocytopenia, and coagulopathy [25,31].…”

Section: Multisystem Inflammatory Syndrome In Children (Mis-c)mentioning

confidence: 99%

Overview of COVID-19 Infection, Treatment, and Prevention in Children

Kao

2024

JCM

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19), caused by the novel respiratory virus—severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)—was declared a global pandemic by the World Health Organization on 11 March 2020. Since then, substantial gains have been made in our understanding of COVID-19 epidemiology, disease presentation, and management. While children tend to have less severe disease courses compared to adults, children can still develop severe COVID-19 infections, particularly in those with underlying medical conditions such as obesity, chronic lung disease, or prematurity. In addition, children are at risk of severe complications of COVID-19 infection, such as multisystem inflammatory syndrome in children (MIS-C) or long COVID. The case definitions of MIS-C and long COVID have continued to evolve with the increased understanding of these new entities; however, improved methods of diagnosis and determination of the optimal management are still needed. Furthermore, with the continued circulation of SARS-CoV-2 variants, there remains a need for clinicians to remain up-to-date on the latest treatment and prevention options. The purpose of this review is to provide an evidence-based review of what we have learned about COVID-19 in children since the start of the pandemic and how best to counsel children and their families on the best methods of prevention.

show abstract

Cardiac complications in children with acute COVID-19 vs multisystem inflammatory syndrome in children (MIS-C)

Cited by 2 publications

References 16 publications

Multisystem Inflammatory Syndrome in Children (MIS-C) Post COVID-19 Infection: Diagnosis and Treatment from the Paediatric Intensive Care Unit (PICU) at a Tertiary Hospital in the Kingdom of Bahrain

Multisystem Inflammatory Syndrome in Children (MIS-C) Post COVID-19 Infection: Diagnosis and Treatment from the Paediatric Intensive Care Unit (PICU) at a Tertiary Hospital in the Kingdom of Bahrain

Overview of COVID-19 Infection, Treatment, and Prevention in Children

Contact Info

Product

Resources

About